{
    "nct_id": "NCT06415656",
    "official_title": "Digital Multi-Vital Sign Monitoring for Early Detection of Cytokine Release Syndrome From Bispecific T-Cell Engagers and Chimeric Antigen Receptor Therapy",
    "inclusion_criteria": "1. Adults at or over the age of 18 with hematologic malignancies undergoing treatment with chimeric antigen receptor (CAR) T-cell therapy or bispecific T-cell engagers (BiTE), as follows:\n\n   * Axicabtagene ciloleucel\n   * Lisocabtagene maraleucel\n   * Brexucabtagene autoleucel\n   * Idecabtagene vicleucel\n   * Ciltacabtagene autoleucel\n   * Obecabtagene autoleucel\n   * Tisagenlecleucel\n   * Blinatumomab\n   * Mosunetuzumab\n   * Talquetamab\n   * Elranatamab\n   * Teclistamab\n   * Glofitamab\n2. Owns a smart phone (e.g., iPhone, Android, Samsung) that is compatible with the VitalTraq app and that can connect to wi-fi. This will be assessed at screening.\n3. Able to read and understand English\n4. Willing and able to provide informed consent to the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Receiving a non-FDA approved CAR-T or BiTE product\n2. Receiving Epcoritamab",
    "miscellaneous_criteria": ""
}